Skip to content
Markets News
Stocks1 min read

CorMedix to Buy Heron Assets in Cash-and-Stock Deal

Makkler Newsroom
November 9, 2026 · Based on reporting by GlobeNewswire

The proposed acquisition adds four commercial-stage products, with CorMedix expecting cost savings and a first-quarter 2027 closing.

Key takeaways

  • CorMedix agreed to pay $145 million in cash and issue 14,583,333 shares for Heron assets.
  • Heron may receive up to $55 million in earn-out payments and royalties.
  • The companies expect the transaction to close in the first quarter of 2027, subject to approvals.

CorMedix Therapeutics agreed to acquire substantially all of Heron Therapeutics’ assets for $145 million in cash and 14,583,333 CorMedix shares. The upfront consideration was valued at about $222.6 million based on CorMedix’s November 6 closing price.

Heron could also receive up to $55 million in earn-out payments tied to ZYNRELEF sales in 2028, along with royalties on certain product sales above a threshold. The deal adds four commercial-stage products: ZYNRELEF, APONVIE, CINVANTI and SUSTOL.

CorMedix said it expects the acquisition to be immediately accretive to earnings and free cash flow after closing. It estimates annualized operating cost synergies of $45 million to $60 million by year-end 2027.

To support the deal, CorMedix entered a $150 million senior secured term loan facility with funds managed by Pharmakon Advisors. It expects to draw $75 million at closing; a second $75 million tranche may be drawn at its discretion through June 30, 2028.

The transaction, unanimously approved by both companies’ boards, is expected to close in the first quarter of 2027. It requires Heron stockholder approval, regulatory clearance and other customary closing conditions. Heron plans to remain publicly traded after the deal and repay its credit facility.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.